{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:04Z","timestamp":1772165704600,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hungarian Brain Research Program","award":["2017-1.2.1-NKP-2017-00002 NAP VI\/4"],"award-info":[{"award-number":["2017-1.2.1-NKP-2017-00002 NAP VI\/4"]}]},{"name":"University of Szeged Open Access Fund","award":["4802"],"award-info":[{"award-number":["4802"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent advances in therapeutic options may prevent deterioration related to Huntington\u2019s disease (HD), even at the pre-symptomatic stage. Be that as it may, a well-characterized patient population is essential for screening and monitoring outcome. Accordingly, the aim of this study was to describe the characteristics of a Hungarian subpopulation of HD patients and mutation carriers diagnosed at the University of Szeged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a search for International Classification of Diseases (ICD) code G10H0 in the local medical database for the period of 1 January 1998 to 31 December 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 90 HD cases (male: 45, female: 45) and 34 asymptomatic carriers (male: 15, female: 19). The median age of onset was 45\u2009years (range: 16\u201379). There were 3 cases of juvenile onset (3.3%), and 7 of late disease onset (7.8%). The median repeat length was 43 (range: 36\u201370) for the pathological and 19 for the non-pathological alleles (range: 9\u201335). 17.5% of the pathological alleles were in the decreased penetrance range, while 7% of non-pathological alleles were intermediate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The genetic and clinical features of the population examined in the present study were in line with the previous Hungarian study, as well as with international literature. The exceptions were the higher ratio of reduced penetrance and intermediate alleles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-021-02089-9","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T18:02:51Z","timestamp":1613671371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetic epidemiological characteristics of a Hungarian subpopulation of patients with Huntington\u2019s disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Katalin","family":"Despotov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9nes","family":"Z\u00e1dori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"Veres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Jakab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"G\u00e1rdi\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eszter","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s Zsigmond","family":"Kincses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e9csei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s","family":"Ajtay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e1niel","family":"Bereczki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Kliv\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"2089_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi SJ. Huntington\u2019s disease: a clinical review. Eur J Neurol. 2018;25:24\u201334.","journal-title":"Eur J Neurol"},{"key":"2089_CR2","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083\u201391.","journal-title":"Mov Disord"},{"key":"2089_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1602\/neurorx.1.2.255","volume":"1","author":"RH Myers","year":"2004","unstructured":"Myers RH. Huntington\u2019s disease genetics. Neurotherapeutics. 2004;1:255\u201362.","journal-title":"Neurotherapeutics"},{"key":"2089_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/ane.12762","volume":"136","author":"AK Roos","year":"2017","unstructured":"Roos AK, Wiklund L, Laurell K. Discrepancy in prevalence of Huntington\u2019s disease in two Swedish regions. Acta Neurol Scand. 2017;136:511\u20135.","journal-title":"Acta Neurol Scand"},{"key":"2089_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/BF00194305","volume":"89","author":"PS Harper","year":"1992","unstructured":"Harper PS. The epidemiology of Huntington\u2019s disease. Hum Genet. 1992;89:365\u201376.","journal-title":"Hum Genet"},{"key":"2089_CR6","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1136\/jnnp.2010.209668","volume":"82","author":"M Orth","year":"2011","unstructured":"Orth M. Observing Huntington\u2019s disease: the European Huntington\u2019s disease Network\u2019s REGISTRY. J Neurol Neurosurg Psychiatry. 2011;82:1409\u201312.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2089_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/mdc3.12442","volume":"4","author":"M Orth","year":"2017","unstructured":"Orth M, Bronzova J, Tritsch C, Ray Dorsey E, Ferreira JJ, Gemperli A. Comparison of Huntington\u2019s disease in Europe and North America. Mov Disord Clin Pract. 2017;4:358\u201367.","journal-title":"Mov Disord Clin Pract"},{"key":"2089_CR8","first-page":"593","volume":"57","author":"NG Ranen","year":"1995","unstructured":"Ranen NG, Stine OC, Abbott MH, Sherr M, Codori AM, Franz ML, et al. Anticipation and instability of IT-15 (CAG)(N) repeats in parent-offspring pairs with Huntington\u2019s disease. Am J Hum Genet. 1995;57:593\u2013602.","journal-title":"Am J Hum Genet"},{"key":"2089_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000479697","volume":"49","author":"E Carrassi","year":"2017","unstructured":"Carrassi E, Pugliatti M, Govoni V, Sensi M, Casetta I, Granieri E. Epidemiological study of Huntington\u2019s disease in the province of Ferrara, Italy. Neuroepidemiology. 2017;49:18\u201323.","journal-title":"Neuroepidemiology"},{"key":"2089_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000008013","volume":"41","author":"K Jakab","year":"1999","unstructured":"Jakab K, G\u00e1rdi\u00e1n G, Endreffy E, Kalm\u00e1r T, Bachrati C, V\u00e9csei L, et al. Analysis of CAG repeat expansion in Huntington\u2019s disease gene (IT-15) in a Hungarian population. Eur Neurol. 1999;41:107\u201310.","journal-title":"Eur Neurol"},{"key":"2089_CR11","doi-asserted-by":"crossref","unstructured":"Apolin\u00e1rio TA, Paiva CLA, Agostinho LA. Intermediate alleles of Huntington\u2019s disease HTT gene in different populations worldwide: a systematic review. Genet Mol Res. 2017;16:1\u201311.","DOI":"10.4238\/gmr16029648"},{"key":"2089_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1399-0004.2010.01388.x","volume":"78","author":"J Sequeiros","year":"2010","unstructured":"Sequeiros J, Ramos EM, Cerqueira J, Costa MC, Sousa A, Pinto-Basto J, et al. Large normal and reduced penetrance alleles in Huntington\u2019s disease: instability in families and frequency at the laboratory, at the clinic and in the population. Clin Genet. 2010;78:381\u20137.","journal-title":"Clin Genet"},{"key":"2089_CR13","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1002\/mds.25172","volume":"27","author":"F Squitieri","year":"2012","unstructured":"Squitieri F, Jankovic J. Huntington\u2019s disease: how intermediate are intermediate repeat lengths? Mov Disord. 2012;27:1714\u20137.","journal-title":"Mov Disord"},{"key":"2089_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153","author":"DR Langbehn","year":"2010","unstructured":"Langbehn DR, Hayden MR, Paulsen JS, Johnson H, Aylward E, Biglan K, et al. CAG-repeat length and the age of onset in Huntington\u2019s disease (HD): a review and validation study of statistical approaches. Am J Med Genet Part B Neuropsychiatr Genet. 2010;153:397\u2013408.","journal-title":"Am J Med Genet Part B Neuropsychiatr Genet"},{"key":"2089_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/ajmg.a.20190","volume":"119 A","author":"L Djouss\u00e9","year":"2003","unstructured":"Djouss\u00e9 L, Knowlton B, Hayden M, Almqvist EW, Brinkman R, Ross C, et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington\u2019s disease. Am J Med Genet. 2003;119 A:279\u201382.","journal-title":"Am J Med Genet"},{"key":"2089_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3233\/JHD-170247","volume":"6","author":"SS Chaganti","year":"2017","unstructured":"Chaganti SS, McCusker EA, Loy CT. What do we know about late onset Huntington\u2019s disease? J Huntingtons Dis. 2017;6:95\u2013103.","journal-title":"J Huntingtons Dis."},{"key":"2089_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/jnnp.48.6.530","volume":"48","author":"RH Myers","year":"1985","unstructured":"Myers RH, Sax DS, Schoenfeld M, Bird ED, Wolf PA, Vonsattel JP, et al. Late onset of Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 1985;48:530\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2089_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/jnnp.66.1.52","volume":"66","author":"T Foroud","year":"1999","unstructured":"Foroud T, Gray J, Ivashina J, Conneally M. Differences in duration of Huntington\u2019s disease based on age at onset. J Neurol Neurosurg Psychiatry. 1999;66:52\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2089_CR19","doi-asserted-by":"crossref","unstructured":"Quarrell O, O\u2019Donovan KL, Bandmann O, Strong M. The prevalence of juvenile Huntington\u2019s disease: a review of the literature and meta-analysis. PLoS Curr. 2012;4:1\u201318.","DOI":"10.1371\/4f8606b742ef3"},{"key":"2089_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s12035-015-9662-8","volume":"54","author":"YM Sun","year":"2017","unstructured":"Sun YM, Zhang YB, Wu ZY. Huntington\u2019s disease: relationship between phenotype and genotype. Mol Neurobiol. 2017;54:342\u20138.","journal-title":"Mol Neurobiol"},{"key":"2089_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0303-8467(80)90017-7","volume":"82","author":"PJH Jongen","year":"1980","unstructured":"Jongen PJH, Renier WO, Gabre\u00ebls FJM. Seven cases of Huntington\u2019s disease in childhood and levodopa induced improvement in the hypokinetic - rigid form. Clin Neurol Neurosurg. 1980;82:251\u201361.","journal-title":"Clin Neurol Neurosurg"},{"key":"2089_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.parkreldis.2018.11.009","volume":"61","author":"M Oosterloo","year":"2019","unstructured":"Oosterloo M, Bijlsma EK, van Kuijk SM, Minkels F, de Die-Smulders CE, Bachoud-L\u00e9vi AC, et al. Clinical and genetic characteristics of late-onset Huntington\u2019s disease. Park Relat Disord. 2019;61:101\u20135.","journal-title":"Park Relat Disord"},{"key":"2089_CR23","unstructured":"Kay C. Population genetics and allele-specific silencing of the Huntington\u2019s disease mutation. Vancouver: University of British Columbia; 2017."},{"key":"2089_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3233\/JHD-190001","volume":"8","author":"FB Rodrigues","year":"2019","unstructured":"Rodrigues FB, Quinn L, Wild EJ. Huntington\u2019s disease clinical trials corner: January 2019. J Huntingtons Dis. 2019;8:115\u201325.","journal-title":"J Huntingtons Dis"},{"key":"2089_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JHD-189001","volume":"7","author":"FB Rodrigues","year":"2018","unstructured":"Rodrigues FB, Wild EJ. Huntington\u2019s disease clinical trials corner: February 2018. J. Huntingtons Dis. 2018;7:89\u201398.","journal-title":"J. Huntingtons Dis."},{"key":"2089_CR26","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","volume":"330","author":"B Kremer","year":"1994","unstructured":"Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, et al. A worldwide study of the Huntington\u2019s disease mutation: the sensitivity and specificity of measuring CAG repeats. N Engl J Med. 1994;330:1401\u20136.","journal-title":"N Engl J Med"},{"key":"2089_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.parkreldis.2014.10.025","volume":"21","author":"JOT Sipil\u00e4","year":"2015","unstructured":"Sipil\u00e4 JOT, Hietala M, Siitonen A, P\u00e4iv\u00e4rinta M, Majamaa K. Epidemiology of Huntington\u2019s disease in Finland. Park Relat Disord. 2015;21:46\u20139.","journal-title":"Park Relat Disord."},{"key":"2089_CR28","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1134\/S1022795418060169","volume":"54","author":"V Zabnenkova","year":"2018","unstructured":"Zabnenkova V, Schagina OA, Galeeva NM, Kopishinskaya SV, Polyakov AV. HTT gene Premutation allele frequencies in the Russian Federation. Russ J Genet. 2018;54:732\u20139.","journal-title":"Russ J Genet"},{"key":"2089_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1399-0004.2006.00668.x","volume":"70","author":"A Semaka","year":"2006","unstructured":"Semaka A, Creighton S, Warby S, Hayden MA. Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clin Genet. 2006;70:283\u201394.","journal-title":"Clin Genet"},{"key":"2089_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/cge.12324","volume":"85","author":"A Semaka","year":"2014","unstructured":"Semaka A, Hayden MR. Evidence-based genetic counselling implications for Huntington\u2019s disease intermediate allele predictive test results. Clin Genet. 2014;85:303\u201311.","journal-title":"Clin Genet"},{"key":"2089_CR31","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/s41436-020-0917-z","volume":"22","author":"H Findlay","year":"2020","unstructured":"Findlay H, Wright GEB, Collins JA, Caron N, Kay C, Xia Q, et al. Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington\u2019s disease in the reduced penetrance range. Genet Med. 2020;22:2108\u201313.","journal-title":"Genet Med"},{"key":"2089_CR32","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1474-4422(20)30343-4","volume":"19","author":"GEB Wright","year":"2020","unstructured":"Wright GEB, Findlay Black H, Collins JA, Gall-Duncan T, Caron NS, Pearson CE, et al. Interrupting sequence variants and age of onset in Huntington\u2019s disease: clinical implications and emerging therapies. Rapid Rev Lancet Neurol. 2020;19:930\u20139.","journal-title":"Rapid Rev Lancet Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02089-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-021-02089-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02089-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T18:06:40Z","timestamp":1613671600000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02089-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2089"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02089-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-41139\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-41139\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"3 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards, as well as approved by the Regional Human Biomedical Research Ethics Committee of the University of Szeged (registration number is 44\/2016). Informed consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Katalin Despotov received support for congress participation from TEVA, and speaker honoraria from Novartis. D\u00e9nes Z\u00e1dori received <\u20091000 EUR honoraria for lectures, travel expenses and registration fees for conferences, educational grants from Hungarian subsidiaries of Abbvie, Abott, Allergan, Goodwill Pharma, Ipsen, Krka, Medis, Medtronic, Sandoz, TEVA and UCB. Regarding this study, the authors did not receive any corporate funding. G\u00e1bor Veres, Katalin Jakab, Gabriella G\u00e1rdi\u00e1n, Eszter T\u00f3th, Tam\u00e1s Zs Kincses, L\u00e1szl\u00f3 V\u00e9csei, Andr\u00e1s Ajtay, D\u00e1niel Bereczki, P\u00e9ter Kliv\u00e9nyi declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}